Compare DexCom, Inc. (DXCM) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares MSCI India ETF — how do they compare? DexCom, Inc. trades at $83.97 (market cap $31.86B), while iShares MSCI India ETF trades at $45.96 (market cap $5.73B). The key difference: DexCom, Inc. is far larger — about 5.6× iShares MSCI India ETF's market cap, and DexCom, Inc. is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and iShares MSCI India ETF for 57 Days on average.
| DXCM | INDA | |
|---|---|---|
Market Cap | $31.86B | $5.73B |
Volume | 3,607,070 | 6,797,522 |
Sector | Health | Broad Market / Factor |
52-Week High | $92.34 | $55.29 |
52-Week Low | $54.84 | $45.42 |
Typical Hold Time | 62 Days | 57 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
INDA is trading at $46.12, down 1.31% with bearish technical signals dominating. The ETF faces headwinds from India's economic challenges including coal power shortages, monsoon concerns, and U.S. tariff tensions. Technical indicators show oversold conditions with RSI readings below 30, while moving averages signal strong bearish momentum. Recent news highlights structural issues in India's banking-heavy market composition despite overall economic growth.
The outlook remains cautious given India's energy security challenges and external trade pressures. Investment opportunity exists for long-term investors betting on India's growth story at current discounted levels, but risks include persistent power shortages, agricultural output concerns, and global trade tensions that could further pressure the ETF's performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
